Achaogen Inc buy klostergang
Summary
This prediction ended on 21.03.19 with a price of €0.50. Massive losses of -95.90% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Achaogen Inc | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by klostergang for this prediction
In the thread Achaogen Inc diskutieren
Achaogen should file for the NDA on Plazomicin
Plazomicin is the company's one late stage and primary drug candidate. It has been developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It was very encouraging data from two Phase 3 studies in Dezember of last year and then again in April of this year that caused the stock to take off. In May, Plazomicin was granted Breakthrough Therapy status for the treatment of bloodstream infections caused by certain Enterobacteriaceae, Klebsiella pneumoniae and Enterobacter aerogenes.
The company plans to submit a NDA to the FDA by end of this year and a marketing application for Europe in the first half of 2018.
Last week, highly ranked (TipRanks) analysts at Stifel Nicolaus ($30 price target) and Leerink Swann ($22 price target) reissued their Buy ratings on Achaogen.